PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting
Rojo-Arnao, María (Hospital Virgen de La Luz (Cuenca))
Martinez-De-la-Casa, José María (Universidad Complutense de Madrid)
Albis-Donado, Oscar (Visual Sense)
Yañez-Castro, Giovanni (Hospital Virgen de La Luz (Cuenca))
Maroto-Cejudo, Raquel (Hospital Virgen de La Luz (Cuenca))
Téllez, Jesús (Institut de Recerca Sant Pau)
Menoyo-Calatayud, Ricardo (Hospital Virgen de La Luz (Cuenca))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Forty-eight eyes from 47 patients were included, with 28 eyes (58. 3%) undergoing the standalone procedure and 20 eyes (41. 7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19. 7 ± 5. 8 mmHg to 11. 4 ± 2. 6 mmHg at 18 months (P < 0. 0001). In the standalone procedure group, preoperative IOP decreased from 21. 5 ± 5. 2 mmHg to 11. 7 ± 2. 5 mmHg (P < 0. 0001), and in the combined procedure group, preoperative IOP decreased from 17. 1 ± 5. 8 mmHg to 10. 9 ± 2. 7 mmHg (P = 0. 0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3. 2 ± 1. 1 to 0. 3 ± 0. 7 in the overall study population (P < 0. 0001). At 18 months, 40 eyes (83. 3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4. 2%) experienced choroidal detachment without visual impairment, two (4. 2%) had transient hyphema, one (2. 1%) showed reactivation of a corneal herpetic ulcer, one (2. 1%) had diplopia, and one (2. 1%) exhibited a shallow anterior chamber during the first week. The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra, i la creació d'obres derivades, sempre que no sigui amb finalitats comercials i que es distribueixin sota la mateixa llicència que regula l'obra original. Cal que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Indian Journal of Ophthalmology, Vol. 72 Núm. 3 (march 2024) , p. 417-426, ISSN 1998-3689

DOI: 10.4103/IJO.IJO_1502_23
PMID: 38153975

10 p, 3.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats